Journal of
Cancer Research and Experimental Oncology

  • Abbreviation: J. Cancer Res. Exp. Oncol.
  • Language: English
  • ISSN: 2141-2243
  • DOI: 10.5897/JCREO
  • Start Year: 2009
  • Published Articles: 53

Full Length Research Paper

The prognostic value of IgA/[EBNA1+VCA-p18] on survival of nasopharyngeal cancer patients

Kartika Widayati Taroeno-Hariadi
  • Kartika Widayati Taroeno-Hariadi
  • Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Jl Kesehatan No. 1 Yogyakarta, DIY, Indonesia.
  • Google Scholar
Djohan Kurnianda
  • Djohan Kurnianda
  • Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Jl Kesehatan No. 1 Yogyakarta, DIY, Indonesia.
  • Google Scholar
Djohan Kurnianda
  • Djohan Kurnianda
  • Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Jl Kesehatan No. 1 Yogyakarta, DIY, Indonesia.
  • Google Scholar
Bambang Hariwiyanto
  • Bambang Hariwiyanto
  • Department of Histology and Cell Biology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Google Scholar
Sagung Rai Indrasari
  • Sagung Rai Indrasari
  • Department of Ear, Nose, Throat, Dr Sardjito Hospital-Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Google Scholar
Camelia Herdini
  • Camelia Herdini
  • Department of Ear, Nose, Throat, Dr Sardjito Hospital-Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Google Scholar
Ibnu Purwanto
  • Ibnu Purwanto
  • Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Jl Kesehatan No. 1 Yogyakarta, DIY, Indonesia.
  • Google Scholar
Salugu Maesadji
  • Salugu Maesadji
  • Department of Radiotherapy, Dr Sardjito Hospital – Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Google Scholar
Retno Dwi Danarti
  • Retno Dwi Danarti
  • Department of Radiotherapy, Dr Sardjito Hospital – Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Google Scholar
Mardiah Suci Hardianti
  • Mardiah Suci Hardianti
  • Department of Internal Medicine, Division of Hematology and Medical Oncology, Faculty of Medicine Universitas Gadjah Mada – Dr. Sardjito Hospital, Jl Kesehatan No. 1 Yogyakarta, DIY, Indonesia.
  • Google Scholar
Ahmad Harijadi
  • Ahmad Harijadi
  • Department of Pathology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
  • Google Scholar
Sofia Mubarika Haryana
  • Sofia Mubarika Haryana
  • Department of Histology and Cell Biology, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Google Scholar


  •  Accepted: 05 March 2014
  •  Published: 31 March 2014

Abstract

Undifferentiated (World Health Organization (WHO) 3) type of nasopharyngeal cancer (NPC) is strongly correlated with Epstein-barr (EBV) virus latent infection. Post-treatment viral reactivation is associated with relapsed or recurrence of NPC. Viral activation can be measured indirectly via plasma IgA responses towards EBV proteins such as EBNA1 and VCA-p18. This study aims at determining the prognostic value of IgA/[EBNA1+VCA-p18] on progression free survival and overall survival of NPC patients. NPC patients aged > 18 years, with locally advanced disease receiving concurrent chemoradiation, with weekly cisplatin 40 mg/m2 samples for blood plasma before treatment, 3 months post-treatment, and at 12 months after treatment completion or at the time of disease progression, whichever came first. An established enzyme linked immunosorbent assay (ELISA) method was used for evaluation of IgA/[EBNA1+VCA-p18] level reported as optical density 450 nm (OD450) values. Forty six NPC patients, with male predominance and mostly in productive age were included. Twenty seven patients had disease progression or died during study follow up. Mean of pre-treatment IgA OD450 was higher in patients with progression compared to those still in remission (2.33 ± 1.08 versus 1.66 ± 1.19, p < 0.05). The higher risk serology group (OD450  ≥ 1.4) had shorter time to progression (RR 6.06; p = 0.014; median time to progression is  13.47 month). Overall survival was not influenced by plasma IgA. Pretreatment IgA/[EBNA-1+VCA-p18] may predict early progression for NPC

 

Key words: Nasopharyngeal cancer, prognosis factor, immunological response, IgA/(EBNA1+ VCA-p18).